Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
Structure Therapeutics Inc. (GPCR)
Company Research
Source: Yahoo! Finance
In preclinical studies, ACCG-2671 demonstrated potent and balanced in vitro activities toward the key amylin receptor and the calcitonin receptor, and also showed robust in vivo efficacy and a pharmacokinetic (PK) and safety profile supporting once-daily oral dosing in humans. The preclinical data demonstrate cagrilintide-like efficacy with an oral small molecule profile, underscoring ACCG-2671's potential as a meaningfully differentiated oral treatment for obesity and related conditions. Was this helpful? Yes No What is the announcement made by Structure Therapeutics Inc. regarding its lead oral small molecule amylin receptor agonist? Structure Therapeutics Inc. announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, which is expected to enter Phase 1 clinical development by year end 2025., a clinical-stage global biopharmaceutical company... announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671.')
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics Inc. (NASDAQ: GPCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
- Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.MarketBeat
- Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of ObesityGlobeNewswire
- Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $80.00 price target on the stock.MarketBeat
- Structure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts [Yahoo! Finance]Yahoo! Finance
GPCR
Sec Filings
- 12/17/24 - Form 8-K
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- GPCR's page on the SEC website